ReviewCurrent diabetes reports2024
Diabetes, SGLT-2 Inhibitors, and Urinary Tract Infection: a Review.
Review in Current diabetes reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 2 syntheses or guidelines pooled it, 44 citations in OpenAlex.
- Are SGLT2 inhibitors really associated with increased urinary tract infection risk? A trial-level meta-analysis across type 2 diabetes, heart failure, and chronic kidney disease.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2026Pooled it
- Pooled it
- Urinary dipstick findings and UTI risk with SGLT2 inhibitors: a post-hoc analysis of the CANVAS and CREDENCE trials.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2026Trial
- Post-marketing safety monitoring of sodium-glucose cotransporter 2 inhibitors for diabetes in cats: a pharmacovigilance study based on the FDA ADAE database.Journal of veterinary internal medicine · 2026Article
- Article
- Global Burden and Temporal Trends of Urinary Tract Infections in Women of Child-Bearing Age in 204 Countries and Territories: A Comprehensive Analysis from 1990 to 2021.International urogynecology journal · 2026Article
- Potential risk signals for drug-related osteomyelitis: a comprehensive disproportionality analysis based on the FDA Adverse Event Reporting System (FAERS) database.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Candidemia Attributed to a Urinary Tract Source: Retrospective Cohort Study of Risk Factors, Clinical Profiles, Therapeutic Approaches and Outcomes.Mycopathologia · 2026Article
- Progress on exercise therapy in type 2 diabetes mellitus with cognitive impairment.Frontiers in sports and active living · 2026Review
- A rationally designed 18-amino acid peptide with potential as GLP-1 receptor agonist.Frontiers in pharmacology · 2026Article
- Targeted next-generation sequencing: a promising approach for pathogen and antimicrobial resistance gene detection in urinary tract infections.Frontiers in microbiology · 2026Article
- Adverse event reporting signals for SGLT-2 inhibitor-metformin combination therapy: a disproportionality analysis of the FAERS database.Frontiers in endocrinology · 2026Article
- Development and validation of a prediction model for urinary tract infection in older patients with type 2 diabetes mellitus.Frontiers in endocrinology · 2026Article
- Exploring the Therapeutic Potential of SGLT-2 Inhibitors in Managing Metabolic Syndrome: A Narrative Review.Current drug research reviews · 2026Review
- Urinary tract infections in diabetes: clinical significance and management approaches.Acta biochimica Polonica · 2026Review
- Analysis of Pharmacological Properties ofLife (Basel, Switzerland) · 2025Review
- Complementary Yet Distinct Roles of GLP-1 Receptor Agonists and SGLT2 Inhibitors in Cardiovascular Risk Reduction.Biomedicines · 2025Review
- Correlating Urinary Tract Infection Risks With Sodium-Glucose Cotransporter-2 Inhibitors: Insights From the National Health Insurance Data of Korea.Journal of Korean medical science · 2025Article
- Single-Cell transcriptomic profiles of peripheral blood immune cells reveal early monocyte and platelet activation in the transition from high-risk states to clinical sepsis.Scientific reports · 2025Article
- 'Case of the Month' from Herlev and Gentofte Hospital, Denmark: candidaemia and fungus ball in a patient with diabetes on sodium-glucose co-transporter 2 inhibitor.BJU international · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewThe aim of this review is to focus on epidemiology, pathogenesis, risk factors, management, and complications of UTI in people with diabetes as well as reviewing the association of SGLT-2 inhibitors with genitourinary infections. RECENT
findingsIndividuals diagnosed with T2DM are more prone to experiencing UTIs and recurrent UTIs compared to individuals without T2DM. T2DM is associated with an increased risk of any genitourinary infections (GUI), urinary tract infections (UTIs), and genital infections (GIs) across all age categories. SGLT2 inhibitors are a relatively new class of anti-hyperglycemic agents, and studies suggest that they are associated with an increased risk of genitourinary infections. The management of diabetes and lifestyle modifications with a patient-centric approach are the most recognized methods for preventing critical long-term complications including genitourinary manifestations of diabetes. The available data regarding the association of SGLT-2 inhibitors with genitourinary infections is more comprehensive compared to that with UTIs. Further research is needed to better understand the mechanisms underlining the association between SGLT-2 inhibitors and genital infections and UTIs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.